Jedd David Wolchok

USPTO Granted Patents = 35 (Patent Applications = 34)

EPO Patents = 8 (Patent Applications = 23)

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 85(Granted Patents)

Company Filing History:

33 out of 559

Memorial Sloan Kettering Cancer Center

Ludwig Institute for Cancer Research Limited

patents

4. 3 out of 269

Icahn School of Medicine at Mount Sinai

patents

5. 1 out of 1

Sloan-kettering Inststute for Cancer Research and the Animal Medical Center

patent

6. 1 out of 1

The Simons Center for Systems Biology at the Institute for Advanced Study

patent

7. 1 out of 512

Sloan-kettering Institute for Cancer Research

patents

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12397029 - Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors (2025-08-26),

2. 12331359 - Neoantigens and uses thereof for treating cancer (2025-06-17),

3. 12252702 - Recombinant poxviruses for cancer immunotherapy (2025-03-18),

4. 12246066 - Anti-CTLA-4 antibodies and methods of use thereof (2025-03-11),

5. 12042534 - Newcastle disease viruses and uses thereof (2024-07-23),

6. 12036279 - Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors (2024-07-16),

7. 11993653 - Antibodies and methods of use thereof (2024-05-28),

8. 11986503 - Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy (2024-05-21),

9. 11884939 - Vaccinia virus mutants useful for cancer immunotherapy (2024-01-30),

10. 11638755 - Anti-CTLA-4 antibodies and methods of use thereof (2023-05-02),

11. 11541087 - Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy (2023-01-03),

12. 11426460 - Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors (2022-08-30),

13. 11401335 - Anti-GITR antibodies and methods of use thereof (2022-08-02),

14. 11345755 - Anti-PD-1 antibodies and methods of use thereof (2022-05-31),

15. 11285209 - Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors (2022-03-29),

Certainly! Here is the article about inventor Jedd David Wolchok:

Title: Innovator Spotlight: Jedd David Wolchok

Introduction: Jedd David Wolchok, a prolific inventor based in New York, NY, has made significant contributions to the fields of oncology, virology, and immunotherapy. With an impressive portfolio of 31 patents, Wolchok's innovative work has focused on developing novel approaches to treating cancer using cutting-edge technologies.

Latest Patents: One of Wolchok's latest patents involves the creation of chimeric Newcastle disease viruses that carry a transgene encoding interleukin-12. These genetically modified viruses, in combination with an antagonist of programmed cell death protein 1 ('PD-1') or its ligand, show promise in enhancing the treatment of cancer. Another notable patent pertains to the use of recombinant MVA or MVAΔE3L expressing human FLT3L as immuno-therapeutic agents against solid tumors, particularly in conjunction with immune checkpoint blockade therapy.

Career Highlights: Throughout his career, Wolchok has collaborated with esteemed institutions such as the Memorial Sloan Kettering Cancer Center and Agenus Inc. His groundbreaking research has led to the development of innovative cancer immunotherapies that have the potential to revolutionize treatment paradigms.

Collaborations: Wolchok has worked closely with distinguished colleagues, including Taha Merghoub and Liang Deng, in advancing the field of cancer immunotherapy. These collaborations have been instrumental in driving forward novel research initiatives and fostering creative solutions to complex medical challenges.

Conclusion: Jedd David Wolchok's trailblazing work in the development of cancer immunotherapies underscores his commitment to advancing the field of oncology. His innovative patents and collaborations reflect a dedication to leveraging cutting-edge technologies for the benefit of patients worldwide, solidifying his reputation as a prominent figure in the realm of medical innovation.

If you need more information or have any other requests, feel free to let me know!

This text is generated by artificial intelligence and may not be accurate.